Pinealon in brief
Pinealon is a programme trade name for the synthetic tripeptide Glu-Asp-Arg (EDR, internal code T-33), C15H26N6O8, 418.40 g/mol as the free peptide, built as two acidic residues followed by arginine. It comes from the Khavinson group at the St Petersburg Institute of Bioregulation and Gerontology, and that group's own literature attributes it to a calf cortex preparation rather than the pineal gland its name suggests. The evidence is mostly spectroscopic DNA and histone studies, transporter docking, and dendritic-spine counts in mouse and induced human neurons, nearly all from one institute and its collaborators. A small human literature also exists in one Russian gerontology journal: open reports in occupational and geriatric groups, mostly of the trade-name preparation used together with a second peptide, measuring biological-age and work-capacity indices rather than clinical endpoints, and one of them reports prooxidant activity and a fall in circulating CD34-positive cells alongside its positive findings. No experimental structure, binding constant or mass spectrum has been published.[1,2,3,4,5,6,7]
Pinealon regulatory status
Pinealon is a research tripeptide with no marketing authorisation found: no FDA, EMA or Health Canada authorisation appears in Drugs@FDA, the EMA medicines database or the Health Canada Drug Product Database, no International Nonproprietary Name has been assigned, and ClinicalTrials.gov lists no registered study using it (all searched November 2026). It is named in none of the three categories of the FDA list of bulk drug substances nominated for compounding under section 503A, in the version updated 14 May 2026, and in neither the table of substances placed in category 2 for significant safety risks nor the table of withdrawn nominations on that agency's safety-risks page, current as of 22 April 2026, so no agency has recorded a concern about it and none has evaluated it. Human reports do exist, and are described in the experiments and unresolved sections below rather than summarised away here: four short papers in one Russian gerontology journal, in occupational and geriatric groups, none of them registered, none reporting randomisation or blinding in the readable abstract, and most of them testing the trade-name preparation together with a second peptide. It is not named on the WADA 2026 Prohibited List; an unapproved pharmacological substance not covered elsewhere on that list would fall under its S0 class of non-approved substances, which is an inference from the class definition rather than a listing of this peptide.[8,9,10,11,12,13,7,14,15,16,17]
Pinealon at a glance
- A synthetic tripeptide, L-glutamyl-L-aspartyl-L-arginine, three residues and 418.40 g/mol as the free peptide, built as two acidic residues followed by arginine: negative charge at the N-terminus, positive at the C-terminus.[1,18,6]
- Pinealon is a programme label rather than a chemical one. In the peer-reviewed literature the molecule is called EDR, Glu-Asp-Arg or the internal code T-33, and the trade name appears mostly in Russian-language reports; the peptide is attributed to the cortical tissue complex Cortexin rather than to the pineal gland its name invokes.[2,5,19]
- The chemistry of an actual sample has been published once, in the 2007 patent, which describes a solution-phase synthesis and isolation as the acetate salt and gives purity, thin-layer mobility, moisture, pH and optical rotation; the figures are on the experiment card. No mass spectrum is reported there or anywhere else found.[6]
- No experimental structure exists, and no binding constant has been measured. What has been measured about its molecular interactions is spectroscopic: fluorescence quenching, which records how far a labelled molecule's light output falls when something comes close to the label rather than how tightly the two bind, against labelled oligonucleotides and wheat histones, plus spectral, NMR and viscometric evidence that it contacts guanine N7 and O6 in the major groove of DNA with magnesium ions enhancing the interaction.[3,20,21]
- The best-quantified biological measurements are cellular morphology: dendritic spine density, the count of the small protrusions through which a neuron receives its contacts, and spine shape class, scored in mouse hippocampal and striatal neurons, with dendrite branching and an oxidative DNA-damage marker measured in induced human neurons. The experimental literature is small, largely from one St Petersburg institute and its collaborators, and one of its figures required a published correction.[4,22,5,23]
- Development status, plainly. There is no International Nonproprietary Name, no marketing authorisation anywhere, no registered clinical trial, and the FDA has neither evaluated the compound as a bulk substance nor recorded any concern about it. Human reports are not absent, which is the part a status line usually gets wrong here: four short papers in one Russian gerontology journal describe use of the trade-name preparation in occupational and geriatric groups, none registered, none describing randomisation or blinding in the readable abstract, and most of them giving it together with a second peptide so that nothing is attributable to this tripeptide alone. One of them reports prooxidant activity by chemiluminescence and significant inhibition of haemopoiesis, read from a fall in circulating CD34-positive cells, beside its positive findings.[8,11,16,17,13,7,14,15]
What is Pinealon?
Pinealon is one of a series of two- to four-residue synthetic peptides developed from the 1990s onward by the group of V. Kh. Khavinson at the St Petersburg Institute of Bioregulation and Gerontology. The series pairs each short sequence with a tissue label and a trade name: AEDG with the pineal gland (Epitalon), KED with the vasculature (Vesugen), AED with cartilage (Cartalax), and this tripeptide, EDR, under the name Pinealon. The labels come from the group's own reading of its experiments rather than from independent classification, and the papers that use them usually print the sequence alongside, which is how a reader can tell which molecule is meant.[2,24,5]
The name and the stated origin do not agree, and the mismatch is worth knowing before reading anything else. The group's own 2020 review describes EDR as a tripeptide isolated from Cortexin, a polypeptide preparation from calf cerebral cortex, and a 2024 methods section states that KED, EDR and AEDG were isolated from the polypeptide complexes of vessels, cerebral cortex and pineal gland respectively. In the one organotypic pineal-gland culture that tested it, EDR left both markers it was measured on unchanged while AEDG raised them. So the pineal in the trade name is not supported by the experiments carried out under that name.[2,5,25]
The comparison readers ask for most often is with Epitalon, and it is answerable on structure and provenance alone. This molecule is the tripeptide Glu-Asp-Arg; Epitalon is the tetrapeptide Ala-Glu-Asp-Gly, a different sequence of a different length with its own registry entries and its own page in this library. The same programme assigns EDR to the cerebral cortex complex and AEDG to the pineal gland, so the tissue labels are the reverse of what the trade names suggest for this one. They have been measured side by side once, in organotypic culture of the pineal gland, where AEDG raised pinealocyte Ki-67 and CGRP staining and EDR changed neither, so the two are not interchangeable even on the tissue whose name EDR carries. Anything beyond that comparison, in either direction, has not been measured in a study that tested both.[25,24,2,5]
The 2007 patent is the document that describes the substance rather than the name. It claims the tripeptide H-Glu-Asp-Arg-OH and a composition based on it, gives the synthetic route and the analytical characterisation of the isolated acetate, and its examples run from toxicology in three species through outgrowth-area measurements on rat cortical explants to microscopy of injured rat spinal cord. It is also the only place found where the physical material is characterised at all, which makes it both indispensable and an interested document.[6]
The supporting literature is narrow and clustered. Searches on the trade name return 22 records, on the sequence 48, and most of what is specific to this molecule comes from one institute and a handful of named collaborators in Rostov-on-Don, Moscow and St Petersburg State University, published largely in Advances in Gerontology and the Bulletin of Experimental Biology and Medicine, often as short reports whose English abstracts carry the finding and not the method, and sometimes no figures at all. Several of those reports also disagree with each other: brain caspase-3 activity is reported lowered in two rat hypoxia experiments and moderately raised in a carotid-occlusion experiment from the same laboratory, and one in vitro report states that these peptides have no direct antioxidant activity and raise the stationary intracellular radical level while lowering the dead-cell fraction, which is the opposite direction to the radical reduction reported elsewhere. Two external contributions stand out: the physics department work on the DNA interaction and the Moscow agricultural-biotechnology work on nucleic-acid and histone binding.[3,20,21,26,27,28,29]
There is also a human literature, and it is thinner than its existence suggests. Four short papers in Advances in Gerontology describe the trade-name preparation in people: workers in locomotive brigades over a two-week period, 32 patients aged 41 to 83 with chronic polymorbidity and an organic brain syndrome in remission, 110 people compared across several unrelated methods, and a study of lorry drivers which PubMed indexes with the publication type Clinical Trial. None is registered on ClinicalTrials.gov, none states randomisation or blinding in the abstract that can be read in English, and three of the four give the preparation together with a second peptide of the same series, so a reported result belongs to the combination rather than to this tripeptide. The endpoints are biological-age and work-capacity indices rather than clinical outcomes. Taken together they are the weakest part of the record rather than the strongest, which is the opposite of how a human study usually reads.[13,7,14,15,11]
Not to be confused with
- Cortexin (a polypeptide complex from calf cerebral cortex)
- A tissue-derived mixture with no single formula or mass, and the material this tripeptide is repeatedly said to have been isolated from. The two are routinely tested side by side and separate on the endpoints measured: in aged rats under hypobaric hypoxia and mild hypothermia the authors report Cortexin acting more strongly than the tripeptide on free-radical readouts and brain caspase-3 activity, while in a Morris maze experiment they rank the tripeptide above Cortexin on the learning index, and in organotypic cortical culture the two differ in the assay concentration at which each acted, with the tripeptide described as the more effective of the pair on serotonin, Ki-67 and vimentin staining. A finding about the complex is not a finding about this molecule.[42,43,19]
- Epitalon / epithalon (AEDG, Ala-Glu-Asp-Gly)
- A tetrapeptide of a different sequence, assigned to the pineal gland by the same programme, with its own registry entries and its own library page. In the one organotypic pineal-gland experiment that tested both, AEDG raised pinealocyte Ki-67 and CGRP staining and this tripeptide did neither, so the two are not interchangeable even on the tissue whose name this one carries.[25,24]
- KED (vesugen), AEDR, EDL, AED (cartalax), EDG, EDP
- Other members of the same synthetic series, each one or two residues different, each given a different tissue label by the same group. The differences are chemically real: in the transporter docking survey EDR ranks first of 26 on LAT1 and on PEPT1 while AEDR and KED rank far lower, and in the mouse spine-morphology experiment EDR and KED moved different parameters. Three-letter codes are easy to transpose, so the sequence rather than the code is the identity.[30,4,22]
- The pineal gland, which the trade name names
- The name points at the pineal gland; the literature attributes the peptide to the cerebral cortex. The review by the originating group calls it a tripeptide isolated from the cortical polypeptide complex Cortexin, and a 2024 methods section assigns KED to vessels, EDR to cerebral cortex and AEDG to pineal gland. The trade name is therefore not evidence of a pineal origin or a pineal target.[2,5,25]
- The abbreviation EDR, and the food peptide DREL, in unrelated literatures
- A PubMed search on the three letters returns mostly papers in which EDR means something else entirely, and a search on the sequence surfaces Asp-Arg-Glu-Leu from a protein hydrolysate, which is a different molecule of a different length. The reliable search handles are the sequence spelled out, the CID and the internal code T-33.[1,19]
Pinealon structure and sequence
The graph is as simple as a peptide gets: glutamate, then aspartate, then arginine, joined head to tail through alpha-carboxyl groups, with a free N-terminal amine on Glu1 and the C-terminal carboxylate on Arg3. PubChem and ChEBI agree on C15H26N6O8, an average mass of 418.40, a monoisotopic mass of 418.18121 and the InChIKey QPRZKNOOOBWXSU-CIUDSAMLSA-N, and the patent writes the same molecule as H-Glu-Asp-Arg-OH and quotes the same formula and mass without the counterion. There are three stereocentres, one per residue, all L, so eight stereoisomers of the sequence exist on paper and only the all-L form is this compound; the one measured stereochemical datum on a real sample is the patent's optical rotation of minus 33 degrees.[1,18,6]
The chemically distinctive feature is the arrangement of charge rather than the amount of it. Glu1 contributes a free gamma-carboxyl, Asp2 a free beta-carboxyl, and Arg3 a guanidinium group that remains protonated across the physiological range, so the molecule carries three acidic groups and two basic ones arranged as an acidic N-terminal end and a basic C-terminal end. The computed descriptors fit that picture: formal charge zero, polar surface area 261 square angstroms, XLogP minus 6.1. The docking survey across the LAT and PEPT transporter families states the dipole explicitly as the reason this peptide topped its ranking, and the general DNA work from the same circle reports that acidic side chains lower the melting temperature of duplex DNA while basic ones raise it, so a molecule carrying both is doing two opposing things at once.[1,30,31]
There is no three-dimensional view on this page, and that is a finding rather than an omission. No experimental structure of the peptide has been deposited, and PubChem reports no computed conformer for the compound either, which is unusual for a molecule of fifteen carbons. Every spatial image of this peptide in the literature, including the rendered picture in the 2020 review and the DNA, histone and transporter complexes, was generated inside modelling software for the purpose of a calculation. A docking pose depicts a hypothesis about a complex; it is not a structure of one.[1,32,30,2]
Three stereocentres, one per residue, all L. PubChem and ChEBI express that as the all-(S) configuration and agree on the standard InChIKey QPRZKNOOOBWXSU-CIUDSAMLSA-N, so eight stereoisomers of this sequence exist on paper and only the all-L form is the molecule described here. There is no cysteine and therefore no disulfide, and no cyclisation, lipidation, PEG, glycosylation or metal coordination. The one measured stereochemical datum on a real sample is the patent's specific optical rotation of minus 33 degrees for its synthesised material. The molecule is formally neutral overall and internally salted: at neutral pH the three carboxylates (two of them free side chains) are balanced by the N-terminal ammonium and the arginine guanidinium, which stays protonated well above physiological pH. PubChem computes a formal charge of 0, eight hydrogen-bond donors, ten acceptors, a topological polar surface area of 261 square angstroms and an XLogP of minus 6.1, which describes an unusually polar small molecule. The acidic-then-basic arrangement, negative charge at the N-terminus and positive at the C-terminus, is the feature every docking study in this literature leans on.[1,18,6,30]
What studies on Pinealon show
Each card names the experimental system and what was measured. A result in one system is not evidence about another.
Peptide synthesis with physico-chemical characterisation, plus a cortical explant assay · Analytical chemistry on the synthesised material; explant fragments of cerebral cortex from Wistar rats
The material was reported at 98.01% by HPLC as an odourless white amorphous powder, with a single thin-layer spot at Rf 0.65 and a specific optical rotation of minus 33 degrees; the explant area index was about 37% above control at day three at the most effective assay concentration of 10 ng/mL.[6]
- Material
- H-Glu-Asp-Arg-OH prepared by solution-phase synthesis with Boc and benzyl protection, DCC and HOBt coupling, purified by preparative reversed-phase HPLC and isolated as the acetate
- Measured
- HPLC purity at 220 nm, thin-layer mobility, moisture, pH of a dilute solution, specific optical rotation; explant outgrowth area index over three days at assay concentrations of 1, 10 and 100 ng/mL
- Compared with
- Untreated explants, area index set to 100%
- Limitation
- A patent is an interested document that was not peer reviewed, and no mass spectrum is reported. The explant readout is a morphometric area index. The experiment did not establish a molecular target, and the clinical material in the same specification is not relied on here.
Khavinson VK et al., 2007, Russian patent RU2301678C1 (applicant Sia Peptides)
Solution-phase physical chemistry of a peptide-DNA interaction · Double-stranded DNA in solution, in low-salt and salted conditions, with and without added magnesium
The peptide was reported to penetrate partly into the major groove of DNA and to contact base atoms, chiefly the N7 and O6 of guanine, and magnesium ions enhanced the interaction by screening the phosphate charges, an effect that persisted in salted solution.[3]
- Material
- Glu-Asp-Arg peptide and duplex DNA
- Measured
- UV and fluorescence spectra, NMR, low-gradient viscometry, and a molecular dynamics simulation of the complex
- Compared with
- DNA without peptide; mono- against divalent cation conditions
- Limitation
- Read as abstract only. The work establishes contact and its ionic dependence, not an affinity: no dissociation constant, no sequence-resolved footprint and no structure of the complex. It is the strongest external physical measurement on this molecule and it concerns generic duplex DNA rather than any named gene.
Silanteva IA et al., 2019, The Journal of Physical Chemistry B
Fluorescence microscopy of labelled peptide uptake, plus fluorescence-quenching titration · HeLa cells; labelled single-stranded and double-stranded deoxyribooligonucleotides and DNA-ethidium complexes in vitro
Labelled peptide was reported in cytoplasm, nucleus and nucleolus, and the quenching constants differed with peptide and with oligonucleotide sequence, including discrimination of cytosine methylation status; this peptide, AEDG and AEDL were reported to prefer CNG-containing oligonucleotides and this peptide and AEDG to prefer CAG-containing ones.[20]
- Material
- Fluorescein-labelled peptides including this tripeptide, alongside AEDG and KEDG; unlabelled peptides for the quenching work
- Measured
- Fluorescence in cytoplasm, nucleus and nucleolus; Stern-Volmer quenching constants against each oligonucleotide
- Compared with
- The other labelled peptides, and oligonucleotides differing in sequence and in cytosine methylation
- Limitation
- Read as abstract only. A fluorescein conjugate is a different molecule from the free peptide and label-driven uptake is a known artefact; a quenching constant reports that something changed the fluorophore's environment, not an affinity or a binding site. The experiment did not establish that the unlabelled peptide enters a nucleus.
Fedoreyeva LI et al., 2011, Biochemistry (Moscow)
Molecular docking against transporter structures · Published structures of the amino-acid carriers LAT1 and LAT2 and the peptide carriers PEPT1 and PEPT2, in silico
This peptide took the best score of the 26 on LAT1 (minus 45.32, against minus 43.40 for EDG and minus 16.59 for AE), the best on PEPT1 (minus 37.59) and second on LAT2 (minus 32.04); on PEPT2 it scored a positive 8.99 and ranked 17th. The authors attribute the ranking to the acidic N-terminus with a neutral or basic C-terminus, and state that a good score is as consistent with inhibiting a carrier as with being carried by it.[30]
- Material
- This tripeptide with free N- and C-termini, among 26 named peptides and peptoids, against a comparison library of 8,400 di- and tripeptides
- Measured
- ICM-Pro docking scores
- Compared with
- Known substrates and inhibitors of each carrier, the other 25 compounds, and the 8,400-peptide background
- Limitation
- Full text read. Docking scores are not transport: no uptake assay, no competition experiment and no mutagenesis was done, and the scores depend on which receptor conformation was chosen. The PEPT2 result shows how far apart two carriers of the same family can place the same molecule. The study did not establish that this peptide enters any cell.
Khavinson VK et al., 2023, Biomolecules
Confocal dendritic-spine morphometry and hippocampal field recording in mice, with DNA docking · 5xFAD mice crossed to a Thy1-EGFP line for spine imaging in hippocampal CA1, and 5xFAD hippocampal slices for long-term potentiation; ten animals per group
Spine density in treated transgenic mice was 12.64 plus or minus 0.31 against 11.31 plus or minus 0.36 per 10 micrometres in saline-treated transgenic mice (p = 0.039), with thin spines 10% lower and mushroom spines unchanged (p = 0.053), while KED moved mushroom spines and not density; the potentiation measurements reached no significance for either peptide. In docking, this peptide scored minus 44.7 at best against minus 26.6 for KED, bound the same minor-groove region with opposite terminal orientation, and the authors report low sequence selectivity across many high-scoring sequences, with the best-scoring masks recurring in the CASP3, NES, GAP43 and APOE promoters.[4]
- Material
- This tripeptide and KED, supplied by one Russian manufacturer, with the animals exposed over a two-month study period; docking of both peptides against all 2,080 unique six-base-pair duplex DNA structures
- Measured
- Spine density per 10 micrometres and the proportions of mushroom, thin and stubby spines; potentiation after high-frequency stimulation; ICM docking scores and the occurrence of the best-scoring sequences in named gene promoters
- Compared with
- Saline-treated transgenic mice, saline-treated non-transgenic littermates, and the two peptides against each other
- Limitation
- Full text read, and this paper carries a published correction: two confocal figures presented as the male and the female comparison were the same image described differently, and both were replaced, with the authors stating the conclusions are unaffected. Spine counts are morphology, not function, and the electrophysiology that would have connected them to function was not significant. The docking half establishes nothing about the cell: the authors note the intracellular concentration of these peptides is unknown and that binding is probably of low selectivity, which is an argument against the sequence-specific reading the same group gives elsewhere.
Khavinson V et al., 2021, Pharmaceuticals
Confocal dendritic-spine morphometry in primary neurons · Mixed cortical-striatal cultures from newborn YAC128 mice expressing human mutant huntingtin and from wild-type littermates, scored in DARPP-32-positive medium spiny neurons at two culture ages, about seven neurons per group
Spine density was 8.4 plus or minus 0.7 per 10 micrometres in wild-type cultures against 5.5 plus or minus 0.4 in transgenic ones; the higher assay concentration of this peptide raised transgenic density toward the wild-type figure, while the lower one changed spine shape toward elongated filopodia-like spines without changing density. KED moved density in one experiment only.[23]
- Material
- This tripeptide at assay concentrations of 20 and 200 ng/mL, added 16 hours before fixation
- Measured
- Spine density per 10 micrometres and spine shape
- Compared with
- Untreated wild-type and transgenic cultures, and KED at the same two assay concentrations
- Limitation
- Full text read. About seven neurons per group with a non-parametric test is a small experiment, the readout is morphology in dissociated culture, and the journal is a low-profile venue outside the indexed literature. The authors describe the link from their DNA-binding measurements to the morphology as supposition. The experiment did not establish what the peptide contacts in these cells.
Khavinson V et al., 2017, Journal of Neurology and Neuroscience
Live-cell imaging and immunofluorescence in transdifferentiated human neurons · Induced cortical neurons made by direct reprogramming of dermal fibroblasts from three elderly female donors
The oxidative DNA-damage signal fell 23% with this peptide, from 0.40 plus or minus 0.04 to 0.31 relative units, where AEDG gave a 10% change that did not reach significance; primary processes rose 28%, from 4.59 plus or minus 0.3 to 5.87 plus or minus 0.5 (p = 0.0208). None of the three peptides changed mitochondrial or lysosomal activity or the p16 level.[5]
- Material
- This tripeptide, KED and AEDG, each stated to have been isolated from a calf tissue polypeptide complex, added to the cultures across a ten-day study period at an assay concentration of 10 micrograms per millilitre
- Measured
- 8-hydroxydeoxyguanosine staining as an oxidative DNA-damage marker, mitochondrial membrane potential and lysosomal signal, p16 protein, and dendrite-tree morphometry
- Compared with
- Untreated induced neurons from the same donors, and the three peptides against one another
- Limitation
- Full text read. Three donor lines, one assay concentration, no sequence-scrambled control, and staining intensity as the endpoint. The peptides are described as isolated from tissue complexes with no purity or identity data given for the material used. The negative results on mitochondria, lysosomes and p16 are as much a part of the finding as the positive ones.
Kraskovskaya N et al., 2024, International Journal of Molecular Sciences
Immunocytochemistry in organotypic tissue culture · Organotypic culture of pineal gland from three-month-old rats
AEDG and KED raised Ki-67 staining and AEDG alone raised CGRP, while this peptide and KE changed neither Ki-67 nor CGRP; none of the four changed AIF. The authors describe the AEDG effect as tissue-specific to the pineal gland.[25]
- Material
- This tripeptide, with AEDG, KED and KE tested alongside
- Measured
- Ki-67 proliferation marker, AIF apoptosis marker and CGRP in pinealocytes
- Compared with
- The other three peptides and untreated cultures
- Limitation
- Read as abstract only, from the originating institute, with staining as the endpoint and no stated concentrations in the abstract. This is the clearest reported non-result for this molecule and it is on the tissue its trade name names, which is why it is included; a reported absence in one short report is not a measured null.
Khavinson VKh et al., 2011, Bulletin of Experimental Biology and Medicine
Rodent model of prenatal hyperhomocysteinemia with offspring behaviour and cell assays · Rats with experimental hyperhomocysteinemia produced by dietary methionine loading through pregnancy, and cerebellar neurons isolated from their offspring
The authors report that the offspring of treated animals performed better on spatial orientation and learning than the offspring of loaded animals without the peptide, and that their isolated cerebellar neurons accumulated less reactive oxygen species and contained fewer necrotic cells.[33]
- Material
- Pinealon (Glu-Asp-Arg), given to the pregnant animals across the loading period
- Measured
- Offspring spatial orientation and learning, reactive oxygen species accumulation in isolated cerebellar neurons, and the proportion of necrotic cells in that population
- Compared with
- Methionine-loaded animals without the peptide, and unloaded controls
- Limitation
- A single laboratory and a model of a dietary insult rather than of a disease, with behaviour and dye-based cell readouts and no molecular target tested. The published figures are not reproduced here because the amounts and the schedule are the form in which the paper reports them. This is the rodent study readers arrive looking for, and it establishes an association between exposure and two downstream readouts, not a mechanism.
Arutjunyan A et al., 2012, International Journal of Clinical and Experimental Medicine
Rodent brain-ischaemia and hypoxia reports with behaviour and caspase-3 activity · Old rats under bilateral carotid artery occlusion, with companion reports from the same laboratory in acute hypoxic hypoxia and in a Morris maze across two age groups
The authors report improved survival after occlusion with either peptide, and for this peptide an increase in behavioural rest with reduced orientation, motivational and motor behaviour. Caspase-3 activity moved in opposite directions across the set: moderately raised in both sham and occluded animals in this report, and reported lowered in two companion papers from the same laboratory, one in acute hypoxic hypoxia and one in the Morris maze experiment, where the peptide also ranked above Cortexin on the learning index.[27]
- Material
- Pinealon, measured beside the cortical polypeptide complex Cortexin
- Measured
- Survival, behavioural categories including rest, orientation, motivation and motor performance, and caspase-3 activity in brain regions, with serum interleukin-6 and tumour necrosis factor in the hypoxia report
- Compared with
- Sham-operated animals, untreated occluded animals, and Cortexin in the same experiments
- Limitation
- Russian-language short reports read as English abstracts only, from one laboratory, with no concentrations, controls or statistics visible in what can be read. The caspase-3 direction is not consistent between them, which is stated here rather than resolved, and a behavioural category is not a disease endpoint. One card covers three reports because they share a laboratory, a comparator and a readout.
Mendzheritskii AM et al., 2011, Advances in Gerontology (Uspekhi Gerontologii)
Open human report in a geriatric population · 32 people aged 41 to 83, 18 men and 12 women, with chronic polymorbidity and an organic brain syndrome of the central nervous system in remission
The authors report an anabolic effect from both preparations and improvement on their biological-age indices, with the KED preparation giving the clearer effect of the two. In the same study they report prooxidant activity by chemiluminescence and a decrease in CD34-positive haematopoietic cell markers, which they describe as significant inhibition of haemopoiesis, and state that neither preparation altered chromatin condensation.[7]
- Material
- The trade-name preparation of this tripeptide and the KED preparation of the same series, studied together
- Measured
- Biological-age indices, chemiluminescence as a measure of oxidant activity, CD34-positive haematopoietic cell markers in blood, and the degree of chromatin condensation
- Compared with
- The two preparations against each other; no control arm is described in the abstract
- Limitation
- An open report of 32 people with no described control arm, no randomisation or blinding stated, read as an English abstract of a Russian-language paper, and testing two peptides together so that nothing in it is attributable to this one alone. The prooxidant and haemopoiesis findings are recorded here because they are what the authors reported and they run against the direction claimed elsewhere in this literature; a finding in an abstract of this kind is not a safety conclusion in either direction.
Meshchaninov VN et al., 2015, Advances in Gerontology (Uspekhi Gerontologii)
What has been measured about Glu-Asp-Arg and DNA, and what has only been calculated
The programme's proposal for the whole series is uniform: a peptide small enough to cross the plasma and nuclear membranes enters the nucleus, binds a short DNA sequence or a histone tail, and changes the transcription of nearby genes. For this tripeptide that proposal has more experimental support than for most of its neighbours, and it is worth separating the two halves. The measured half is physical chemistry on generic DNA: spectral, NMR, viscometric and molecular-dynamics work from a university physics department reports the peptide partly entering the major groove and contacting guanine N7 and O6, with magnesium ions strengthening the interaction by screening the phosphate charges, and fluorescence-quenching titrations report sequence-dependent and methylation-dependent interaction with short oligonucleotides, with labelled histones, and modulation of two eukaryotic endonucleases hydrolysing phage DNA, an experiment whose abstract names no peptide individually and whose peptide set includes this one according to the group's own later systematic review.[3,20,21,34,24]
The calculated half is where the named genes come from, and the group's own calculations do not agree with each other. A docking score is a number software produces for how well two modelled shapes fit together, not a quantity measured on a sample, and the scores below are all of that kind. A 2016 docking paper over 19 peptides assigns short four-base sites to several of them; the 2020 review states two sites for this peptide, d(CCTGCC) and d(CCAGC), and reports matches in the PPARA, PPARG, SOD2, GPX1 and TPH1 promoters; the 2021 paper docks it against all 2,080 unique six-base-pair duplexes and reports instead that many sequences score similarly, that GC-rich ones score better, and that binding is therefore probably of low selectivity, before listing recurrences of its best-scoring masks in the CASP3, NES, GAP43 and APOE promoters. A separate modelling paper assigns it histone H1.3 and the Fkbp1b gene, and a 2022 review adds a further promoter analysis crediting this peptide with 22% of the sites that passed its threshold and listing a different gene set again. These are different answers to the same question, all computed, and the low-selectivity finding undercuts the promoter lists published beside it.[35,2,4,36,37]
What is missing from the chain is the step that would make it mechanism rather than correlation. There is no measured affinity for any sequence, no structure of the peptide bound to anything, and no experiment in which a promoter site was mutated and the response to the peptide changed. Entry into cells is likewise modelled rather than shown for the free peptide: the docking survey ranks it first of 26 on LAT1 and PEPT1 while noting that such a score is equally consistent with blocking a carrier, and the one imaging experiment that put this peptide inside nuclei used a fluorescein conjugate. The downstream readouts that are attributed to the mechanism, serotonin and marker expression in cortical cultures, caspase-3 in rat brain, irisin gene expression, sit several inferential steps away from it.[30,20,38,39]

What is still unknown about Pinealon
Identity is settled; the material is not. Sequence, formula, both masses, stereochemistry and the InChIKey agree across PubChem, ChEBI and the patent, and the patent adds purity, mobility, moisture, pH and optical rotation for a real synthesised sample isolated as the acetate. What no public document states is which form or counterion any particular non-pharmaceutical preparation contains: PubChem carries 'Pinealon acetate salt form' as a bare synonym with no record behind it, and the CAS number it lists could not be confirmed at the registry. No mass spectrum of this peptide was found anywhere, and no independent analytical identification of it in any finished material.[1,18,6]
The structural file is empty, and emptier than usual. No deposited structure, no NMR structure, no circular dichroism, no crystal, and no computed conformer in PubChem either, so there is no three-dimensional representation of this molecule that anyone has measured. For a peptide whose proposed mechanism is sequence-specific binding, the obvious experiments have not been published: no dissociation constant against a defined oligonucleotide, no footprint, no structure of a complex. The group's own docking work reports low selectivity across thousands of sequences, which is the strongest internal argument against the specific promoter sites listed elsewhere in the same literature.[1,32,4,2]
Replication and provenance are the second gap. Most of what is specific to this molecule comes from one institute and its named collaborators, much of it in short-report format where concentrations, controls and statistics are not visible in the publicly readable English abstract, and the two most quantitative biological papers are a journal outside the indexed literature and a paper that required a correction for two duplicated confocal figures. The clearly external contributions are the physical-chemistry and nucleic-acid work, and those measure interactions with DNA and histones in solution rather than anything about cells. No study found anywhere used a sequence-scrambled control peptide.[4,23,3,21]
The human record is the gap most likely to be misread, because a reader told only that no controlled trial is registered will conclude there is nothing. Four short papers in one Russian gerontology journal do describe the trade-name preparation in people, and they are weak evidence for three separate reasons rather than one: none is registered or reports randomisation or blinding in a readable abstract, three of the four give it together with a second peptide of the same series, and the endpoints are composite biological-age or work-capacity indices rather than clinical outcomes. They also do not point one way. The largest of them to state its population reports an anabolic effect and improved indices alongside prooxidant activity by chemiluminescence and a fall in circulating CD34-positive cells that the authors call significant inhibition of haemopoiesis. No independent group has published a human study of this peptide, and nothing in this set would support a statement about safety in either direction.[13,7,14,15,11]
The tissue label is the least evidenced part of the identity. The name points at the pineal gland, the literature attributes the peptide to a cortical tissue complex, and in the one pineal-gland culture that tested it the peptide changed neither marker measured while the pineal-labelled tetrapeptide changed both. Meanwhile the measured work on this molecule is spread across HeLa cells, rat cerebellar granule cells, neutrophils, PC12 cells, rat skin explants, rat offspring under dietary methionine loading, mouse hippocampal and striatal neurons and reprogrammed human fibroblasts. A reader should treat the trade name as a catalogue string and the sequence as the subject.[25,2,5,40,41,33]
Key papers on Pinealon
- Peptide stimulating regeneration of central nervous system neurons, pharmaceutical composition based on thereof and method for its using.
Khavinson VK, Grigoriev EI, Malinin VV, Ryzhak GA (2007), Russian patent RU2301678C1 (applicant Sia Peptides) · Patent with synthesis, characterisation and animal and explant examples
The only document that describes a real sample of this peptide rather than a name: the synthetic route, the acetate isolation, the HPLC purity, the thin-layer spot, the optical rotation and the cortical explant assay. Read it knowing it is a patent and an interested document.
- Role of Mono- and Divalent Ions in Peptide Glu-Asp-Arg-DNA Interaction.
Silanteva IA, Komolkin AV, Morozova EA, Vorontsov-Velyaminov PN, Kasyanenko NA (2019), The Journal of Physical Chemistry B · Solution-phase spectroscopy, NMR, viscometry and molecular dynamics
The most convincing physical measurement on this molecule, and from outside the originating institute: where on DNA it makes contact, which base atoms, and how that depends on mono- and divalent cations. Abstract only unless you have access.
- Feasibility of Transport of 26 Biologically Active Ultrashort Peptides via LAT and PEPT Family Transporters.
Khavinson VK, Linkova NS, Rudskoy AI, Petukhov MG (2023), Biomolecules · Molecular docking against transporter structures
The most quantitative treatment of the peptide's chemistry anywhere, and a lesson in how to read a docking table: first of 26 on two carriers, 17th with a positive score on a third, and the authors themselves noting that a good score may mean inhibition rather than transport. Open access.
- Neuroprotective Effects of Tripeptides-Epigenetic Regulators in Mouse Model of Alzheimer's Disease.
Khavinson V, Ilina A, Kraskovskaya N, Linkova N, Kolchina N, Mironova E, Erofeev A, Petukhov M (2021), Pharmaceuticals · Spine morphometry and field recording in mice, with DNA docking
The fullest experiment in this literature and the best illustration of its limits: measured spine morphology with numbers and p-values, an electrophysiology arm that reached no significance, a docking arm reporting low sequence selectivity beside a list of named promoters, and a published figure correction. Open access.
- Interaction of short peptides with FITC-labeled wheat histones and their complexes with deoxyribooligonucleotides.
Fedoreyeva LI, Smirnova TA, Kolomijtseva GY, Khavinson VKh, Vanyushin BF (2013), Biochemistry (Moscow) · Fluorescence-quenching titration against labelled histones
Read it with its companion paper for the whole of the experimental evidence that this peptide interacts with histones, and to see how indirect that evidence is: quenching constants against labelled wheat histones, with no affinity and no mapped contact.
- Effect of short peptides on expression of signaling molecules in organotypic pineal cell culture.
Khavinson VKh, Linkova NS, Chalisova NI, Dudkov AV, Koncevaya EA (2011), Bulletin of Experimental Biology and Medicine · Organotypic pineal culture with immunocytochemistry
A short report in which this peptide changed neither marker measured, in culture of the gland its trade name names, while the pineal-labelled tetrapeptide changed both. Rare in this literature and worth reading for that reason.
- EDR Peptide: Possible Mechanism of Gene Expression and Protein Synthesis Regulation Involved in the Pathogenesis of Alzheimer's Disease.
Khavinson V, Linkova N, Kozhevnikova E, Trofimova S (2020), Molecules · Narrative review from the originating institute
The review that collects the programme's claims for this molecule in one place, which makes it the fastest way to see which statements rest on measurements and which on docking. It is also where the Cortexin origin is stated plainly, against the trade name. Open access.
- [Effect of synthetic peptides on aging of patients with chronic polymorbidity and organic brain syndrome of the central nervous system in remission]
Meshchaninov VN, Tkachenko EL, Zharkov SV, Gavrilov IV, Katyreva IuE (2015), Advances in Gerontology (Uspekhi Gerontologii) · Open human report in a geriatric population
The human report that states its population and reports findings in both directions, including prooxidant activity and a fall in CD34-positive cells beside its positive indices. Read it to see how far this literature's human evidence actually reaches. Russian-language, English abstract only.
References
- 1.National Center for Biotechnology Information. PubChem Compound Summary for CID 10273502, Glu-Asp-Arg. PubChem. source · database record
- 2.Khavinson V, Linkova N, Kozhevnikova E, Trofimova S. (2020). EDR Peptide: Possible Mechanism of Gene Expression and Protein Synthesis Regulation Involved in the Pathogenesis of Alzheimer's Disease. Molecules. 26:159. doi:10.3390/molecules26010159 · full text read
- 3.Silanteva IA, Komolkin AV, Morozova EA, Vorontsov-Velyaminov PN, Kasyanenko NA. (2019). Role of Mono- and Divalent Ions in Peptide Glu-Asp-Arg-DNA Interaction. The Journal of Physical Chemistry B. 123:1896-1902. doi:10.1021/acs.jpcb.8b10359 · abstract only
- 4.Khavinson V, Ilina A, Kraskovskaya N, Linkova N, Kolchina N, Mironova E, Erofeev A, Petukhov M. (2021). Neuroprotective Effects of Tripeptides-Epigenetic Regulators in Mouse Model of Alzheimer's Disease. Pharmaceuticals. 14:515. doi:10.3390/ph14060515 · full text read · corrected: Corrected in Pharmaceuticals 2025;18:111 (PMID 39861198, PMC11769113): two confocal figures, presented as the male and the female comparison, were the same image described differently. The authors state the conclusions are unaffected and both figures were replaced.
- 5.Kraskovskaya N, Linkova N, Sakhenberg E, Krieger D, Polyakova V, Medvedev D, Krasichkov A, Khotin M, Ryzhak G. (2024). Short Peptides Protect Fibroblast-Derived Induced Neurons from Age-Related Changes. International Journal of Molecular Sciences. 25:11363. doi:10.3390/ijms252111363 · full text read
- 6.Khavinson VK, Grigoriev EI, Malinin VV, Ryzhak GA. (2007). Peptide stimulating regeneration of central nervous system neurons, pharmaceutical composition based on thereof and method for its using. Russian patent RU2301678C1 (applicant Sia Peptides). source · full text read
- 7.Meshchaninov VN, Tkachenko EL, Zharkov SV, Gavrilov IV, Katyreva IuE. (2015). [Effect of synthetic peptides on aging of patients with chronic polymorbidity and organic brain syndrome of the central nervous system in remission]. Advances in Gerontology (Uspekhi Gerontologii). 28:62-67. PMID 26390612 · abstract only
- 8.U.S. Food and Drug Administration. (2026). Drugs@FDA: FDA-Approved Drugs. Drugs@FDA database. source · database record
- 9.European Medicines Agency. (2026). Medicines: search for human medicines (centrally authorised medicines). European Medicines Agency medicines database. source · database record
- 10.Health Canada. (2026). Drug Product Database online query. Health Canada Drug Product Database. source · database record
- 11.U.S. National Library of Medicine. (2026). ClinicalTrials.gov study search. ClinicalTrials.gov. source · database record
- 12.World Anti-Doping Agency. (2025). World Anti-Doping Code International Standard: Prohibited List 2026. World Anti-Doping Agency. source · full text read
- 13.Nazimko VA, Morgul EV, Petrova OA, Sheikhova RG, Kozina LS, Savenko MA, Lysenko DS. (2012). [Analysis of some parameters of biological age and adaptation possibilities of workers of locomotive brigades]. Advances in Gerontology (Uspekhi Gerontologii). 25:57-62. PMID 22708445 · abstract only
- 14.Myakotnykh VS, Torgashov MN, Egorin KV, Meshchaninov VN, Gavrilov VI, Borovkova TA, Zvezdina EM, Verzhbitskaya TY, Tkachenko EL. (2016). [Comparative analysis of different methods of geroprotective]. Advances in Gerontology (Uspekhi Gerontologii). 29:594-601. PMID 28539017 · abstract only
- 15.Bashkireva AS, Artamonova VG. (2012). [The peptide correction of neurotic disorders among professional truck-drivers]. Advances in Gerontology (Uspekhi Gerontologii). 25:718-728. PMID 23734521 · abstract only
- 16.U.S. Food and Drug Administration. (2026). Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act. U.S. Food and Drug Administration. source · full text read
- 17.U.S. Food and Drug Administration. (2026). Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. U.S. Food and Drug Administration. source · full text read
- 18.ChEBI, European Bioinformatics Institute. Glu-Asp-Arg, CHEBI:156374. ChEBI. source · database record
- 19.Umnov RS, Lin'kova NS, Khavinson VKh. (2014). Peptides stimulate expression of signal molecules in neuronal cultures from animals of different age. Bulletin of Experimental Biology and Medicine. 157:701-704. doi:10.1007/s10517-014-2646-2 · abstract only
- 20.Fedoreyeva LI, Kireev II, Khavinson VKh, Vanyushin BF. (2011). Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA. Biochemistry (Moscow). 76:1210-1219. doi:10.1134/S0006297911110022 · abstract only
- 21.Fedoreyeva LI, Smirnova TA, Kolomijtseva GY, Khavinson VKh, Vanyushin BF. (2013). Interaction of short peptides with FITC-labeled wheat histones and their complexes with deoxyribooligonucleotides. Biochemistry (Moscow). 78:166-175. doi:10.1134/S0006297913020053 · abstract only
- 22.Kraskovskaya NA, Kukanova EO, Lin'kova NS, Popugaeva EA, Khavinson VK. (2017). Tripeptides Restore the Number of Neuronal Spines under Conditions of In Vitro Modeled Alzheimer's Disease. Bulletin of Experimental Biology and Medicine. 163:550-553. doi:10.1007/s10517-017-3847-2 · abstract only · corrected: Correction in Bull Exp Biol Med 2017;163:699 (PMID 28975591), which restates the funding acknowledgement only.
- 23.Khavinson V, Linkova N, Kukanova E, Bolshakova A, Gainullina A, Tendler S, Morozova E, Tarnovskaya S, Vinski DSP, Bakulev V. (2017). Neuroprotective Effect of EDR Peptide in Mouse Model of Huntington's Disease. Journal of Neurology and Neuroscience. 8:166. doi:10.21767/2171-6625.1000166 · full text read
- 24.Khavinson VK, Popovich IG, Linkova NS, Mironova ES, Ilina AR. (2021). Peptide Regulation of Gene Expression: A Systematic Review. Molecules. 26:7053. doi:10.3390/molecules26227053 · full text read
- 25.Khavinson VKh, Linkova NS, Chalisova NI, Dudkov AV, Koncevaya EA. (2011). Effect of short peptides on expression of signaling molecules in organotypic pineal cell culture. Bulletin of Experimental Biology and Medicine. 152:138-141. doi:10.1007/s10517-011-1473-y · abstract only
- 26.Mendzheritskii AM, Karantysh GV, Ryzhak GA, Dem'ianenko SV. (2014). [Regulation of content of cytokines in blood serum and of caspase-3 activity in brains of old rats in model of sharp hypoxic hypoxia with Cortexin and Pinealon]. Advances in Gerontology (Uspekhi Gerontologii). 27:94-97. PMID 25051764 · abstract only
- 27.Mendzheritskii AM, Karantysh GV, Ivonina KO. (2011). [Effects of introduction of short peptides before carotid artery occlusion on behaviour and caspase-3 activity in the brain of old rats]. Advances in Gerontology (Uspekhi Gerontologii). 24:74-79. PMID 21809624 · abstract only
- 28.Kozina LS. (2008). [Investigation of antihypoxic properties of short peptides]. Advances in Gerontology (Uspekhi Gerontologii). 21:61-67. PMID 18546825 · abstract only
- 29.Kozina LS, Arutiunian AV, Stvolinskii SL, Khavinson VKh. (2008). [Biological activity of regulatory peptides in model experiments in vitro]. Advances in Gerontology (Uspekhi Gerontologii). 21:68-73. PMID 18546826 · abstract only
- 30.Khavinson VK, Linkova NS, Rudskoy AI, Petukhov MG. (2023). Feasibility of Transport of 26 Biologically Active Ultrashort Peptides via LAT and PEPT Family Transporters. Biomolecules. 13:552. doi:10.3390/biom13030552 · full text read
- 31.Solovyev AY, Tarnovskaya SI, Chernova IA, Shataeva LK, Skorik YA. (2015). The interaction of amino acids, peptides, and proteins with DNA. International Journal of Biological Macromolecules. 78:39-45. doi:10.1016/j.ijbiomac.2015.03.054 · abstract only
- 32.RCSB Protein Data Bank. Full-text search of the Protein Data Bank for 'pinealon' and 'Glu-Asp-Arg tripeptide'. RCSB PDB search API. source · database record
- 33.Arutjunyan A, Kozina L, Stvolinskiy S, Bulygina Y, Mashkina A, Khavinson V. (2012). Pinealon protects the rat offspring from prenatal hyperhomocysteinemia. International Journal of Clinical and Experimental Medicine. 5:179-185. PMID 22567179 · full text read
- 34.Khavinson VKh, Fedoreyeva LI, Vanyushin BF. (2011). Site-specific binding of short peptides with DNA modulated eukaryotic endonuclease activity. Bulletin of Experimental Biology and Medicine. 151:66-70. doi:10.1007/s10517-011-1261-8 · abstract only
- 35.Khavinson VK, Lin'kova NS, Tarnovskaya SI. (2016). Short Peptides Regulate Gene Expression. Bulletin of Experimental Biology and Medicine. 162:288-292. doi:10.1007/s10517-016-3596-7 · abstract only
- 36.Kuznik BI, Davydov SO, Popravka ES, Lin'kova NS, Kozina LS, Khavinson VK. (2019). [Epigenetic Mechanisms of Peptide-Driven Regulation and Neuroprotective Protein FKBP1b]. Molekuliarnaia Biologiia. 53:339-348. doi:10.1134/S0026898419020095 · abstract only
- 37.Ilina A, Khavinson V, Linkova N, Petukhov M. (2022). Neuroepigenetic Mechanisms of Action of Ultrashort Peptides in Alzheimer's Disease. International Journal of Molecular Sciences. 23:4259. doi:10.3390/ijms23084259 · full text read
- 38.Khavinson VKh, Lin'kova NS, Tarnovskaya SI, Umnov RS, Elashkina EV, Durnova AO. (2014). Short peptides stimulate serotonin expression in cells of brain cortex. Bulletin of Experimental Biology and Medicine. 157:77-80. doi:10.1007/s10517-014-2496-y · abstract only
- 39.Khavinson VKh, Kuznik BI, Tarnovskaya SI, Lin'kova NS. (2016). Short Peptides and Telomere Length Regulator Hormone Irisin. Bulletin of Experimental Biology and Medicine. 160:347-349. doi:10.1007/s10517-016-3167-y · abstract only
- 40.Voicekhovskaya MA, Chalisova NI, Kontsevaya EA, Ryzhak GA. (2012). Effect of bioregulatory tripeptides on the culture of skin cells from young and old rats. Bulletin of Experimental Biology and Medicine. 152:357-359. doi:10.1007/s10517-012-1527-9 · abstract only
- 41.Khavinson V, Ribakova Y, Kulebiakin K, Vladychenskaya E, Kozina L, Arutjunyan A, Boldyrev A. (2011). Pinealon increases cell viability by suppression of free radical levels and activating proliferative processes. Rejuvenation Research. 14:535-541. doi:10.1089/rej.2011.1172 · abstract only
- 42.Mendzheritsky AM, Karantysh GV, Ryzhak GA, Prokofiev VN. (2015). [Pinealon and Cortexin influence on behavior and neurochemical processes in 18-month aged rats within hypoxia and hypothermia]. Advances in Gerontology (Uspekhi Gerontologii). 28:532-539. PMID 28509493 · abstract only
- 43.Mendzheritski AM, Karantysh GV, Abramchuk VA, Ryzhak GA. (2013). [Effect of peptide geroprotectors on the navigation system learning and caspase-3 in brain structures in rats of different age]. Advances in Gerontology (Uspekhi Gerontologii). 26:252-257. PMID 28976148 · abstract only
- 44.ChemSpider. Glu-Asp-Arg, ChemSpider record 8448980. ChemSpider, Royal Society of Chemistry. source · database record
Related entries
- Epithalon (epitalon)Epithalon is a four-residue synthetic peptide (Ala-Glu-Asp-Gly) modelled on the amino-acid composition of a bovine pineal extract. It has been studied mainly for its effect on telomere length in cell culture.
- CartalaxCartalax is the trade name one Russian research programme gives the synthetic tripeptide L-alanyl-L-glutamyl-L-aspartic acid (Ala-Glu-Asp, one-letter AED). It is a member of the Khavinson short-peptide bioregulator series and the same sequence as Epitalon minus its C-terminal glycine.
- SemaxSemax is a synthetic corticotropin-fragment peptide designed in Moscow in the 1980s and in Russian medical use since. It is made by joining residues 4 to 7 of adrenocorticotropic hormone to a Pro-Gly-Pro tail.
